WO2004002511A1 - 抗hiv剤 - Google Patents
抗hiv剤 Download PDFInfo
- Publication number
- WO2004002511A1 WO2004002511A1 PCT/JP2003/008259 JP0308259W WO2004002511A1 WO 2004002511 A1 WO2004002511 A1 WO 2004002511A1 JP 0308259 W JP0308259 W JP 0308259W WO 2004002511 A1 WO2004002511 A1 WO 2004002511A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- mbp
- virus
- cells
- evaluation method
- Prior art date
Links
- 0 CCCN*C* Chemical compound CCCN*C* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a novel use of a mannose binding protein (MANNOSE BINDING PROTE IN, hereinafter simply referred to as "MBP”), particularly to a human immunodeficiency virus (HUMAN IMMUNODEF I CIENCY VIRUS, hereinafter simply referred to as "HIV”).
- MBP mannose binding protein
- HAV human immunodeficiency virus
- MBP is a substance called mannan-binding protein, mannan-binding lectin, mannose-binding lectin, etc., and a C-type lectin having a collagen-like structure and a calcium-requiring sugar-recognition region in its molecule, namely collectin.
- the MBP generally has an N-terminal region (cystine-rich region), a collagen-like region, a neck region, and a N-terminal region from its N-terminal side to the C-terminal side (from left to right in FIG. 4). It is composed of four regions, the sugar recognition region (CRD). Then, due to the helical structure in the neck region and the collagen-like region, three polypeptides of about 30 kDa to about 33 kDa are intermolecularly bonded to each other to form a single subunit structure of about 90 kDa to about 99 kDa (trimer ) Is formed. Two to six of the subunit structures are further combined in a bouquet-like manner to form a homo-oligomer structure.
- CCD sugar recognition region
- MBP binds to the sugar chains on the surface of the microorganism, activates the complement system, and participates in the initial defense against microbial infection against microorganisms that have entered the organism [Holmskov, U. eta, Immunol. Today, 15, pp. 67-74 (1994) and Turner, MW et al. a, Immunol. Today, ⁇ , pp. 532-540 (1996)].
- the susceptibility of infectious disease to MBP-deficient individuals [Su Marauder fiel d, JA et ah, Lancet, 345, pp.
- subtype B virus As mentioned above, despite the fact that subtype B virus is widely distributed worldwide, its vaccine is still under study and its practical use is far from being realized.
- the subtype E virus, CRF0 and AE are highly infectious and are expected to expand their range in the future. Some subtype D viruses show fulminant types. Therefore, the development of an effective drug against viruses belonging to such a subtype is also expected.
- AIDS vaccines include live vaccines that use AIDS virus virions as they are, component vaccines that use parts of virions, recombinant vaccines obtained by recombining viral genes, and killing of viruses. Killed vaccines that retain only the protein structure have been studied. However, considering their practicality, it is necessary to consider not only the protective effect of HIV infection, that is, efficacy (induction of immune competence), but also its safety.
- HAART combination therapy
- HIV is a virus with a high degree of genomic diversity, and is thought to have two main causes.
- Reverse transcriptase is 3 ' ⁇ Since it lacks 5 'exonuclease activity, it does not have a proofreading function for the replicated nucleotide sequence. Also, since the substrate specificity of reverse transcriptase is low, mutations such as substitution, deletion, insertion and duplication of bases occur very frequently during the reverse transcription reaction [Mansky, LM, J. Gen. Virol., 79, pp. 1373-1345 (1998)].
- HIV grows in vivo at a rate of 1091 G / day [Perelson, AS et al., Science, m, pp. 1582-1586 (1996)], and replicates 300 cycles a year. Is believed to be Thus, mutations begin to accumulate at the same time as HIV infection, resulting in further genomic diversity.
- Second is the increase in diversity due to genetic recombination between viruses of different strains. Genetic recombination of a retrovirus to which HIV belongs is usually performed by the incorporation of two homologous RNA genomes into the virus particle and the reverse transcriptase-type ⁇ ⁇ immediately switch function (te immediately late switch). Forced copy choice is known to occur frequently by a mechanism called [Coffin, JM, J. Gen. Virol., 42, pp.1-26 (1979)] [Jetzt, AE et a!., J. Virol., 74, pp.1234-1240 (2000)]. Therefore, it is thought that acquiring such a high degree of genomic diversity will cause HIV quasispecies, subtype differentiation, emergence of recombinant virus, drug resistance mutation, CTL escape mutation, etc. I have.
- HIV is roughly divided into two types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2), according to genetic lineage. HIV-1 is further divided into group M, group 0 and group N. being classified.
- Group M is the most major group of HIV-1 and is classified into nine subtypes AD, FH, J and K. Subtypes I and F have been further subdivided into sub-subtypes A, A2 and Fl, F2, respectively.
- subtype E Since subtype E is currently being classified as CRF0 and AE, subtype E is referred to as “CRF0 and AE” (described above) in this specification.
- HIV-2 has been classified into subtypes A to G [Charneau, P. et al., Virology, 205, pp. 247-253 (1994); Gurtler, LG et al., J. Virol., 68, pp. 1581-1585 (1994); Simon, F. et ah, Nat. Med., 4, pp.1032-1037 (1998); Triques, K. et al., AIDS Res. Hum. Retroviruses, j_6, pp.139-151 (2000); Robertoson, DL et al., Science, 288, pp.55- 56 (2000); Triques, K. et al., Virology, 259, pp. 99-109 (1999)].
- Glycoproteins of HIV include gpl20, an envelope glycoprotein, and gp41, a transmembrane glycoprotein. These glycoproteins are produced by the cleavage of gpl60, encoded by a viral genome-like gene called "env", with a host protease [Hallenberger, S. et al., Nature, 360, pp. 358-361] (1992)].
- gpl20 has 24 N-linked sugar chain binding sites [Leonard, CK et al., J. Biol. Chem., 265, pp. 10373-10382 (1990)]. Because it accounts for about half [Allans, JS et al., Science, 228, pp.1091-1094 (1985)], it can be said that HIV is a virus covered with sugar chains.
- Various experiments have shown that gpl20 sugar chains are required for HIV infection of target cells [Fennie, C. et al., J. Virol., 63-PP.639-646 ( Natl. Acad. Sci. USA, 84, pp. 5424-5428 (1987); Montefiori, DC et al., Proc. Natl. Acad. Sci. USA, 85 pp. 9248-9252 (1988); Pal, R. et al., Proc. Natl. Acad. Sci. USA, 86, pp. 3384-3388 (1989)].
- chemokine receptor co-receptor for macrophage tropic virus
- CXCR4 co-receptor for T cell tropic virus
- CCR1, CCR2b, CCR3, CCR4, CCR8, CCR9, CXCR2, CXCR5, CXCR6 / STRL33 and CX3CR1 have been reported.
- a virus mediated by CCR5 as Colecept Yuichi is a CCR5 (also simply referred to as R5) directional virus
- a virus mediated by CXCR4 as Colecept Yuichi is a CXCR4 (also referred to simply as X4) directional virus. Therefore, it is classified into CCR1 tropic virus, CCR2b tropic virus and the like.
- the R5 tropic virus is a macrophage tropic virus
- the X4 tropic virus is classified as a T cell tropic virus.
- R5X4 tropic viruses are classified as viruses that are tropic to both macromerges and T cells.
- MBP binds to gpl20 [Larkin, M. et al., AIDS, 3, pp. 793-798 (1989); Mizuochi, T. et al., J. Biol. Chem. , 264, pp. 13834-13839 (1989); Saifuddin, M. et ah, L Gen. Virol., 81, pp. 949-955 (2000)].
- MBP has anti-HIV effects and whether MBP Whether or not it was for production was unknown at all. These indicate that, despite being the most important factor in determining the utility of MBP as an anti-HIV agent, it has never been proven. In addition, since there was no evaluation system capable of evaluating the anti-HIV effect of MBP, the development of anti-HIV drugs using MBP was not progressing.
- R5 tropic virus is hardly neutralized by neutralizing antibodies and is deeply involved in the progression of the disease state.
- treatment of R5 tropic virus in the early stages of infection is likely to have a profound effect on the prognosis of patients, so that appropriate treatment of R5 tropic virus during initial infection Is required.
- CCR5 since most of the transmitted HIV is CCR5 directional virus, CCR5 has also attracted attention as a target for preventive treatment and infection / transmission control.
- chemokine receptors The existence of such chemokine receptors has only recently been discovered, and the development of therapeutics targeting these chemokine receptors is still in the basic research stage. Development of these chemokine receptor inhibitors has also been developed, but there is concern that administration of CCR5 inhibitors will speed up the emergence of CXCR4-directed virus and contribute to the progression of the disease state. Major issues of concern remain unresolved.
- the present invention has been made in view of the problems pointed out in the prior art described above.
- the present inventors have established for the first time an evaluation system capable of quantifying the anti-HIV activity of MBP. is there.
- the use of this evaluation system proved for the first time the anti-HIV effect of MBP, that is, the effect of suppressing HIV proliferation, and opened up the use of MBP as an anti-HIV agent.
- the present inventors have proved that MBP has an anti-HIV effect not only on sub-human HIV type E HIV but also on HIV belonging to other clades (sub-types).
- the gist of the present invention lies in an anti-HIV agent containing MBP as an active ingredient.
- MBP since the target of MBP is a sugar chain, it is advantageous in that it is less affected by the emergence of MBP-resistant strains due to HIV genome mutation.
- MBP has the advantage that it does not have the side effects observed with compounds used in conventional chemotherapy because it is a substance resident in the living body.
- a method for evaluating anti-HIV activity that is, (1) culturing infected cells obtained by coexisting target cells and HIV, and (2) culturing the infected cells. Wash to get clean cells,
- a method for evaluating the anti-HIV effect exerted by MBP, including the steps, is also provided. According to another aspect of the present invention, another method for evaluating an anti-HIV effect,
- a method for evaluating the anti-HIV effect exerted by MBP, including the steps, is also provided.
- FIG. 1 is a graph showing the correlation between recombinant mannose-binding protein (rMBP) and HIV activity in HIV-infected cells NDK / M8166.
- rMBP mannose-binding protein
- FIG. 2 is a graph showing the correlation between recombinant mannose-binding protein (rMBP) and HIV activity in HIV-infected cells LP65 / M8166.
- rMBP mannose-binding protein
- FIG. 3 is a graph showing the correlation between native mannose-binding protein (nMBP) and HIV activity in HIV-infected cells NDK / M8166.
- nMBP native mannose-binding protein
- FIG. 4 is a schematic diagram showing the structure of a mannose binding protein.
- the anti-HIV agent of the present invention utilizes the HIV growth inhibitory effect of MBP used as an active ingredient, for example, the HIV neutralizing effect and the HIV germination inhibitory effect. It is useful for treatment and suppression of disease progression.
- MBP which is an active ingredient in the anti-HIV agent of the present invention
- MBP isolated and purified from human serum and animal cells preferably Chinese hamster ovary (CH0) cells (hereinafter simply referred to as "(; H0 cells"), are genetically secreted as MBP.
- CH0 Chinese hamster ovary
- rhMBP Recombinant human mannan-binding protein
- rhMBP Recombinant human mannan-binding protein
- the expression number pNOWl-hMBP is constructed by introducing the sequence number: 2) into the plasmid pNOWl, and (ii) the expression vector pNOWl-hMBP is introduced into dihydrofolate reductase-deficient (dhfr) CH0 cells.
- the expression vector pNOWl-hMBP is constructed.
- the amino acids that make up nhMBP have been analyzed and reported by Herman et al. [Sastry et al., The human mannose-binding protein gene. Exonstructure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10 "". 170 (4), pp. 1175-1189 (1989)]
- the amino acid sequence constituting nhMBP is shown in SEQ ID NO: 3.
- a human liver cDNA library (manufactured by Clonelac) is amplified from the start codon to the stop codon of nhMBP, and the obtained nhMBP cDNA is digested with restriction enzymes to obtain nhMBP cDNA.
- SEQ ID NO: 2 contiguous polynucleotides
- the expression vector PN0W1 is digested with restriction enzymes, and the insert described above is inserted between pCMV and BGP polyA using a DNA ligation kit (Takara Shuzo).
- the expression vector obtained in this way is named Plasmid pNOW1-hMBP.
- the expression vector pNOW 1 -hMBP is introduced into dihydrofolate reductase deficient (dhfr) CH0 cells as follows. IM Prepare IMDM medium (GIBC0) supplemented with fetal serum, mix with (dhfr-) DG44 CH0 cell line, and incubate at 37 with 5% CO2 for 24 hours.
- dhfr dihydrofolate reductase deficient
- the culture supernatant is discarded, and instead, the expression vector pNOWl-hMBP is mixed with a ribofectin solution, IMCS containing FCS containing a previously prepared solution is added thereto, and hypoxanthine (GIBC0 ) And thymidine (manufactured by GIBCO), followed by culturing to introduce the expression vector pNOW1-hMBP into dhfr-host CH0 cells. Then, discard the culture supernatant, add FCS, hypoxanthine, and IMDM with thymidine, and further culture.
- GIBC0 hypoxanthine
- IMDM thymidine
- neomycin (G418) resistant CH0 cells cells into which expression vector pNOW1-hMBP has been introduced are cultured, and then treated with trypsin, and the cells are treated with FCS-containing IMDM containing neomycin (G418). Suspend. The suspension is then seeded on a microplate and cultured for 2 weeks at 37 ° C and 5% carbon dioxide (CO2) to produce neomycin-resistant cells (clones). Select some clones from which rhMBP production has been confirmed, and culture each clone. Discard each culture supernatant, add IMCS with FCS of the same composition as above, culture for 4 days, and collect the culture supernatant.
- rhMBP Measure the amount of rhMBP produced in the collected culture supernatant.
- the amount of rhMBP produced was determined using the anti-Egret polyclonal antibody (expressed in Escherichia coli) against the sugar recognition region (CRD) and the neck region of collectin, nhMBP as a control, and nhMBP (quantitative measurement).
- CCD sugar recognition region
- nhMBP as a control
- nhMBP quantitative measurement
- rhMBP-producing clones are further subcultured and stabilized, and then a low-concentration methotrexate is added to the medium for gene amplification.
- each selected cell clone was mixed and seeded with IMDM supplemented with 10% dialyzed FCS (manufactured by IRH Bioscience) supplemented with methotrexate and neomycin (G418).
- FCS dialyzed by IRH Bioscience
- the clone with the highest production efficiency among the clones obtained is inoculated and cultured. Then, discard the culture supernatant, add CHO-S-SFMII medium containing methotrexate and neomycin (G418) (add vitamin C so that the final concentration will be 100 mM when vitamin C is added), Cultivate for 4 days. The culture supernatant is collected, dialyzed against TBS (prepared from TBS powder (manufactured by Takara Shuzo)), and then dialyzed against TBSC (5 mM CaCh, TBS). Thereafter, purification is performed using mannan-agarose (manufactured by SIGMA).
- mannan-agarose is packed in a column (Collum PD-10, Empty, manufactured by Pharmacia), dialyzed culture solution is passed through the column, washed with TBSC, and then washed with TBSE (10 m EDTA, TBS). Elute. After elution, add 1M CaCh to a final concentration of 15 mM. Then, apply to mannan-agarose again, wash with TBSC, and elute with TBS containing 100 mM mannose. After that, dialysis is again performed on TBSC to obtain a purified rhMBP product.
- Collum PD-10 Empty, manufactured by Pharmacia
- the purified rhMBP thus obtained shows a specific peak at a molecular weight of 1,000 to 1,300 kDa, particularly at a molecular weight of l, 150 kDa, when processed by gel filtration chromatography at 280 nm. Show. It also has a molecular weight of 200-400 kDa, especially 300 It shows a specific peak at a molecular weight of kDa.
- the gel filtration chromatographic analysis of rhMBP was performed using 20 mM Tris-HCl (pH 8.0) and 0.15 mM NaCK 5 mM EDTA at a flow rate of 0.5 ml / min. 30 ( ⁇ l OmmX length 300 recitations; manufactured by Pharmacia). Then, 40 ⁇ g of rhMBP is passed through this column, and the absorbance at 280 nm is measured.
- the above-mentioned purified rhMBP is preferably used.
- this purified rhMBP is further applied to gel filtration chromatography, the fractions appearing at a molecular weight of 1,000 to 1, 300 kDa and those appearing at a molecular weight of 200 to 400 kDa are obtained by measuring the absorbance at 280 nm. Or a purified rhMBP containing both of these fractions.
- the anti-HIV agent of the present invention acts effectively on any type of HIV strain, but as is clear from the description in the Examples below, the HIV-1 group M In addition to HIV belonging to subtype B, it exerts remarkable anti-HIV activity against HIV belonging to subgroup D of HIV-1 group M and recombinant endemic strains, particularly strain CRF01-AE.
- the anti-HIV agent of the present invention also exerts a remarkable anti-HIV action on CCR5-tropic virus, CXCR4-tropic virus, and CCR5 / CXCR4-tropic virus. Furthermore, the anti-HIV agent of the present invention also exhibits a remarkable anti-HIV effect on macrophage tropic virus, T cell tropic virus, and macrophage / T cell tropic virus.
- the anti-HIV agent of the present invention is used as a therapeutic agent for AIDS or an agent for suppressing the progression of the pathogenesis of HIV infection
- a dosage form and an administration route such as intravenous administration
- an administration route such as intravenous administration
- transmucosal administration in addition to intravenous administration, transmucosal administration, transdermal administration, intramuscular administration, subcutaneous administration, rectal administration, oral administration and the like can be appropriately selected.
- it can be used as various forms of preparation.
- the blood MBP concentration was 0.18 to 4.35 ⁇ g / ml for Wild / Wild (average 1.26 g / ml), 0.00 to 0.80 zg / ml for Wild / mutant (average 0.23 / g / ml), nmtant / mutanat It has also been reported to be 0.00 to 0.20 g / ml (average 0.04 g / ml) [Akushi Hiroyuki et al., History of Medicine, 194 (12), pp.957-958 (2000)].
- the intravenous dose of the anti-HIV agent of the present invention is such that the blood MBP concentration of a healthy person is about 1 g / It is about 1.5 g / ml to about 1.5 g / ml.
- the amount of MBP produced may decrease due to liver damage such as hepatitis C or may be caused by genetic mutation.
- the dose may be determined so that the blood MBP concentration is about 1 g / ml to about 1.5 g / ml.
- the effective blood MBP level it is necessary to monitor the HIV-RNA level and the CD4 positive cell count regularly, to determine the relationship between the monitoring results and the MBP dose, and to determine the effective blood MBP level. If the blood MBP level is normal, gradually increase the blood level (e.g., about 1.5 / g / nil to about 5.0 g / ml), and periodically check the amount of HIV-RNA and the number of CD4-positive cells. After monitoring the relationship between the monitoring results and the MBP dose, the effective blood MBP concentration may be determined.
- the effective blood concentration of MBP is not fixed because it depends on the concentration of MBP in the blood of the individual, but is preferably about 1.0 g / ml to about 50 g / ml, more preferably about 1.0 g / ml.
- the concentration is preferably set to 1.5 ig / ml to about 10 / xg / ml, and the blood concentration immediately before or immediately after administration may be outside these ranges.
- genetic mutations can also reduce blood MBP levels, so MBP doses should be determined in consideration of gene mutations.
- dosage forms such as oral dosage form, injection, suppository, etc.
- solvents excipients, coatings, bases, binders, lubricants, disintegrants, dissolution aids
- Ingredients, suspending agents, thickeners, emulsifiers, stabilizers, buffers, tonicity agents, soothing agents, preservatives, flavoring agents, fragrances, coloring agents, etc. be able to.
- Solvents purified water, water for injection, saline, laccase oil, ethanol, glycerin.
- Excipients starches, lactose, glucose, sucrose, crystalline cellulose, calcium sulfate, calcium carbonate, talc, titanium oxide, trehalose, xylitol.
- Coatings sucrose, gelatin, cellulose acetate phthalate, and the polymeric excipients listed above.
- Vaseline vegetable oil, macrogol, oil-in-water emulsion base, water-in-oil emulsion base.
- Binders starch and derivatives thereof, cellulose and derivatives thereof, gelatin, sodium alginate, tragacanth, natural polymer compounds such as gum arabic, synthetic polymer compounds such as polybierpyrrolidone, dextrin, hydroxypropyl starch.
- Lubricants Stearic acid and its salts, talc, waxes, wheat starch, macrogol, hydrogenated vegetable oils, sucrose fatty acid esters, polyethylene glycol.
- Disintegrator Starch and its derivatives, agar, gelatin powder, sodium bicarbonate, cellulose and its derivatives, carmellose calcium, hydroxypropyl starch, carboxymethylcellulose and its salts and their frames Bridge, low-substituted hydroxypropylcellulose.
- Thickener Carmellose sodium, polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, tragacanth, gum arabic, sodium alginate.
- Emulsifiers Gum arabic, cholesterol, tragacanth, methylcellulose, various surfactants, lecithin.
- Stabilizer Sodium bisulfite, ascorbic acid, tocophere, chelating agents, inert gases, reducing substances.
- Proforce hydrochloride, lidocaine, benzyl alcohol Benzoic acid and its salts, p-hydroxybenzoic acid esters, chlorobutanol, inverted soap, benzyl alcohol, phenol, tyromesal.
- Flavors Sucrose, saccharin, Canzo extract, sorbitol, xylitol, glycerin.
- Colorants Water-soluble food coloring and lake coloring.
- the anti-HIV agent of the present invention may contain a pharmaceutically acceptable salt in addition to the above-mentioned components.
- the pharmaceutically acceptable salt (s) include salts with bases such as inorganic bases and organic bases, and acid addition salts such as inorganic acids, organic acids, basic or acidic amino acids, and the like. Specific examples of such salt (s) are Although illustrated, the present invention is not limited to these.
- Inorganic base Alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, aluminum, ammonium and the like.
- Organic bases Primary amines such as ethanolamine, getylamine, diethanolamine, dicyclohexylamine, secondary amines such as ⁇ , ⁇ '-dibenzylethylenediamine, trimethylamine, triethylamine, pyridine, picoline, Tertiary amines such as triethanolamine.
- Hydrochloric acid hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid.
- Formic acid acetic acid, lactic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, benzoic acid, cunic acid, succinic acid, malic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, ⁇ -toluenesulfonic acid .
- Basic amino acids arginine, lysine, orditin.
- the term of the anti-HIV effect demonstrated in the following examples includes not only a neutralizing effect on HIV but also a germination inhibitory effect on HIV, but for convenience, it is simply referred to as "neutralizing effect”. It is described.
- Table 1 summarizes the details of the HIV strains used in Examples 1 and 2.
- Virus Strain Direction Chemokine Receptor r-subtype
- HIV-NDK experimental strain subtype D; hereinafter simply referred to as “NDK”
- LP65 recombinant epidemic strain
- HIV strains are composed of a human peripheral blood mononuclear cell (human PBMC; hereinafter simply referred to as “PBM (;)”) blasted with phytohemagglutinin (PHA) and a T cell line.
- PBM human peripheral blood mononuclear cell
- PHA phytohemagglutinin
- T cell line a T cell line
- NDK and M8166 are strains available from the National Institutes of Health (NIH) AIDS Research and Reference Regent Program.
- nhMBP purified from human blood and rhMBP synthesized by the method described in International Publication No. WO99 / 37676 were used.
- NDK a fulminant virus
- PBMC and M8166 were cultured at 37 ° C for 1 hour to infect
- LP65 was added to PBMC and M8166, respectively, and these were cultured at 37 for 1 hour for HIV infection.
- Of virus was added to 5 x 10 6 cells / ml.
- the obtained infected cells were named "LP65 / PBMCj" and "LP65 / M8166", respectively. Thereafter, the infected cells were washed twice with PBS.
- nhMBP or rhMBP was applied to the four virus-infected cells (NDK / PBMC, Awake66, LP65 / PBM LP65 / M8166) at a concentration of l-100 g / ml (Fig. 1) or 1-30 g / ml. It was added at a concentration of ml (Figs. 2-3). The concentration of the cells at this time is a concentration of 1 ⁇ 10 6 cells / ml per 200 1 (that is, 2 ⁇ 10 5 cells / 200 1).
- the anti-HIV agent of the present invention exhibits an anti-HIV effect on both subtype E HIV and subtype D HIV. Similarly, it has also been found that the anti-HIV agent of the present invention has an anti-HIV activity against CCR5 / CXCR4 tropic virus and macrophage / T cell tropic virus.
- Example 2
- a 92Th014 experimental strain (subtype B) and a JRCSF experimental strain (subtype B) were prepared. All of these experimental strains are available from the National Institutes of Health, AIDS Research and Reference Program.
- the PBM nhMBP and rhMBP described in Example 1 were used.
- 100 TCID 5 100 TCID 5 .
- a virus solution 50 ⁇ 1 corresponding to a titer of, and a solution 501 of nhMBP or rhMBP with final concentrations of 2, 6, 20, and 60 g / ml were mixed. Then, this mixed solution is cultured for 1 hour in the presence of 37T: 5% carbon dioxide to adjust the final concentration of nhMBP or rhMBP to 1, 3, 10, or 30 Aig / ml.
- a system was prepared.
- the amount of HIV-derived p24 antigen in the culture supernatant was measured by EUSA using a fully automatic chemiluminescence enzyme immunoassay system (Lumipulse f: manufactured by Fujirebio). Comparison was made with the group without MBP.
- the anti-HIV agent of the present invention also exhibited an anti-HIV action against CCR5-tropic virus and macrophage-tropic virus.
- MBP was directly proved to show anti-HIV activity against CCR5-directed virus, so that MBP could be used not only in the early stage of HIV infection but also in prevention. It was also found that it can be used effectively for treatment and for controlling infection and transmission.
- the anti-HIV agent of the present invention also exhibited an anti-HIV effect against CCR5 / CXCR4 tropic virus. Instead, it has proved to be effective in conditions with an advanced clinical course (ie, not only for HIV-infected individuals but also for HIV patients).
- MBP which showed anti-HIV activity against CCR5 / CXCR4-directed virus, showed similar anti-HIV activity against CCR5-directed virus. Therefore, MBP is considered to also exhibit anti-HIV activity against CXCR4-directed virus. Similarly, MBP, which showed an anti-HIV effect on macrophage T cell-directed virus, showed a similar anti-HIV effect on macrophage-directed virus. However, it is thought to show anti-HIV activity.
- the anti-HIV agent of the present invention shows that the anti-HIV agent of the present invention is also effective against CCR5 tropic virus, CXCR4 tropic virus, and CCR5 / CXCR4 tropic virus. It has become clear that it exhibits HIV effects. In addition, it has also been found that the anti-HIV agent of the present invention exhibits an anti-HIV action against macrophage tropic virus, T cell tropic virus, and macrophage T cell tropic virus.
- the anti-HIV agent of the present invention containing MBP as an active ingredient exhibits neutralizing activity against various HIV strains including the recombinant epidemic strain CRF0 and AE virus, which are most difficult to neutralize the activity.
- the anti-HIV agent of the present invention is not limited to the virus subtype, chemokine receptor tropism, macrophage ZT cell tropism type and degree. It exhibits a certain anti-HIV effect on HIV type B, subtype D HIV, and CRF01-AE.
- the anti-HIV agent of the present invention also has an anti-HIV activity against CCR5-tropic virus, CXCR4-tropic virus, and CCR5 / CXCR4-tropic virus.
- the anti-HIV agent of the present invention also has an anti-HIV action against macrophage tropic virus, T cell tropic virus, and macrophage cell tropic virus.
- the anti-HIV agent of the present invention targets a sugar chain, there is little possibility that an MBP-resistant strain will appear due to HIV genome mutation.
- MBP itself resides in vivo, there are no side effects observed with compounds used in conventional HIV treatment.
- the anti-HIV agent of the present invention can cope with various infectious diseases caused by HIV, and is extremely useful in the treatment thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03738567A EP1518557A4 (en) | 2002-06-28 | 2003-06-30 | ANTI-HIV AGENTS |
CA002472438A CA2472438A1 (en) | 2002-06-28 | 2003-06-30 | Mannose binding protein for use in anti-hiv treatment |
US10/500,774 US20050123899A1 (en) | 2002-06-28 | 2003-06-30 | Anti-hiv agent |
JP2004517323A JPWO2004002511A1 (ja) | 2002-06-28 | 2003-06-30 | 抗hiv剤 |
AU2003246119A AU2003246119B2 (en) | 2002-06-28 | 2003-06-30 | Anti-HIV agent |
US11/691,946 US20070190652A1 (en) | 2002-06-28 | 2007-03-27 | Anti-HIV Agent |
US11/691,914 US20070191265A1 (en) | 2002-06-28 | 2007-03-27 | Anti-HIV Agent |
US11/691,921 US20070184477A1 (en) | 2002-06-28 | 2007-03-27 | Anti-HIV Agent |
US12/169,502 US20090048165A1 (en) | 2002-06-28 | 2008-07-08 | Anti-hiv agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002189534 | 2002-06-28 | ||
JP2002-189534 | 2002-06-28 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/691,914 Division US20070191265A1 (en) | 2002-06-28 | 2007-03-27 | Anti-HIV Agent |
US11/691,921 Division US20070184477A1 (en) | 2002-06-28 | 2007-03-27 | Anti-HIV Agent |
US11/691,946 Division US20070190652A1 (en) | 2002-06-28 | 2007-03-27 | Anti-HIV Agent |
US12/169,502 Continuation US20090048165A1 (en) | 2002-06-28 | 2008-07-08 | Anti-hiv agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004002511A1 true WO2004002511A1 (ja) | 2004-01-08 |
Family
ID=29996851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/008259 WO2004002511A1 (ja) | 2002-06-28 | 2003-06-30 | 抗hiv剤 |
Country Status (7)
Country | Link |
---|---|
US (5) | US20050123899A1 (ja) |
EP (1) | EP1518557A4 (ja) |
JP (1) | JPWO2004002511A1 (ja) |
CN (2) | CN1620307A (ja) |
AU (1) | AU2003246119B2 (ja) |
CA (1) | CA2472438A1 (ja) |
WO (1) | WO2004002511A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013535483A (ja) * | 2010-08-06 | 2013-09-12 | イリイチ・エプシテイン オレグ | P24タンパク質の産生を阻害するか又は排出を促進する医薬組成物及び方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103857690B (zh) * | 2011-08-19 | 2017-04-05 | 艾昆西恩斯公司 | 蛋白质检测 |
WO2014113459A1 (en) * | 2013-01-15 | 2014-07-24 | Duke University | Hiv-1 neutralizing factor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000069894A2 (en) * | 1999-05-14 | 2000-11-23 | Steffen Thiel | Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
JP2002165591A (ja) * | 2000-09-25 | 2002-06-11 | Jsr Corp | 磁性粒子およびその使用方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270199A (en) * | 1987-08-20 | 1993-12-14 | The Children's Medical Center Corporation | Human mannose-binding protein |
DE69330709T2 (de) * | 1992-12-28 | 2002-07-11 | Canon Kk | Blickrichtungsdetektor und Kamera mit diesem Detektor |
JPH06202200A (ja) * | 1993-01-07 | 1994-07-22 | Minolta Camera Co Ltd | カメラ |
ES2166779T3 (es) * | 1993-05-07 | 2002-05-01 | Bio Merieux Inc | Complejos inmunogenicos del hiv. |
JP3272870B2 (ja) * | 1994-07-29 | 2002-04-08 | キヤノン株式会社 | カメラ |
JPH11206378A (ja) * | 1998-01-23 | 1999-08-03 | Fuso Pharmaceutical Industries Ltd | 組換えヒトマンナン結合タンパク質およびその製造方法 |
EP1109019A1 (en) * | 1999-12-15 | 2001-06-20 | BioStrands S.r.l. | Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease |
US20030109023A1 (en) * | 2000-05-11 | 2003-06-12 | Hiroshi Miyake | HIV-producing cell line and uses thereof |
DE60130994T2 (de) * | 2000-07-07 | 2008-07-24 | New York University | Anti-hiv und anti-tumor lysozympeptide sowie fragmente |
AU2001278416A1 (en) * | 2000-07-13 | 2002-01-30 | Natimmune A/S | Mannan-binding lectin (mbl) treatment of infections in individuals treated with tnf-alphainhibitors |
DE10109813A1 (de) * | 2001-03-01 | 2002-09-12 | Thomas Stanislawski | Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen |
JP2002345756A (ja) * | 2001-05-25 | 2002-12-03 | Canon Inc | 視線検出装置及び光学機器 |
JP4272863B2 (ja) * | 2002-09-20 | 2009-06-03 | キヤノン株式会社 | カメラおよびカメラシステム |
-
2003
- 2003-06-30 CA CA002472438A patent/CA2472438A1/en not_active Abandoned
- 2003-06-30 CN CNA038024578A patent/CN1620307A/zh active Pending
- 2003-06-30 WO PCT/JP2003/008259 patent/WO2004002511A1/ja active Application Filing
- 2003-06-30 JP JP2004517323A patent/JPWO2004002511A1/ja active Pending
- 2003-06-30 AU AU2003246119A patent/AU2003246119B2/en not_active Ceased
- 2003-06-30 EP EP03738567A patent/EP1518557A4/en not_active Withdrawn
- 2003-06-30 US US10/500,774 patent/US20050123899A1/en not_active Abandoned
- 2003-06-30 CN CN200610079267XA patent/CN1876833B/zh not_active Expired - Fee Related
-
2007
- 2007-03-27 US US11/691,914 patent/US20070191265A1/en not_active Abandoned
- 2007-03-27 US US11/691,921 patent/US20070184477A1/en not_active Abandoned
- 2007-03-27 US US11/691,946 patent/US20070190652A1/en not_active Abandoned
-
2008
- 2008-07-08 US US12/169,502 patent/US20090048165A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000069894A2 (en) * | 1999-05-14 | 2000-11-23 | Steffen Thiel | Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
JP2002165591A (ja) * | 2000-09-25 | 2002-06-11 | Jsr Corp | 磁性粒子およびその使用方法 |
Non-Patent Citations (5)
Title |
---|
EZEKOWITZ R. ET AL.: "A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 169, no. 1, 1989, pages 185 - 196, XP002972231 * |
JUN'ICHI MIMAYA ET AL.: "Ketsuyubyo to HIV kansen no genjo", IGAKU NO AYUMI, vol. 176, no. 1, 1996, pages 7 - 11, XP002972234 * |
See also references of EP1518557A4 * |
TADASHI HARADA ET AL.: "HIV kansen to men'eki", IGAKU NO AYUMI, vol. 176, no. 1, 1996, pages 44 - 48, XP002972233 * |
TADASHI HARADA: "HIV no kansen o soshi suru tanpaku-shitsu", CLINICAL IMMUNOLOGY, vol. 21, no. 11, 1989, pages 1782 - 1787, XP002972232 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013535483A (ja) * | 2010-08-06 | 2013-09-12 | イリイチ・エプシテイン オレグ | P24タンパク質の産生を阻害するか又は排出を促進する医薬組成物及び方法 |
Also Published As
Publication number | Publication date |
---|---|
US20090048165A1 (en) | 2009-02-19 |
JPWO2004002511A1 (ja) | 2005-10-27 |
CA2472438A1 (en) | 2004-01-08 |
CN1620307A (zh) | 2005-05-25 |
EP1518557A1 (en) | 2005-03-30 |
EP1518557A4 (en) | 2008-12-03 |
AU2003246119B2 (en) | 2008-02-21 |
US20050123899A1 (en) | 2005-06-09 |
CN1876833B (zh) | 2010-08-11 |
US20070184477A1 (en) | 2007-08-09 |
US20070190652A1 (en) | 2007-08-16 |
AU2003246119A1 (en) | 2004-01-19 |
US20070191265A1 (en) | 2007-08-16 |
CN1876833A (zh) | 2006-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6861059B2 (en) | Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations | |
JP2012508160A (ja) | ワクチン組成物 | |
US7335727B2 (en) | Pharmaceutical used for treating HIV infection, the composition and uses thereof | |
US8603965B2 (en) | Pharmaceutical composition for the prophylaxis and treatment of HIV infection and its use | |
Bean | New drug targets for HIV | |
TW202110475A (zh) | Tlr7調節化合物及hiv疫苗之組合 | |
US20090048165A1 (en) | Anti-hiv agent | |
US6686333B1 (en) | Inhibition of HIV replication using soluble Tat peptide analogs | |
JP5692933B2 (ja) | 免疫刺激HIVTat誘導体ポリペプチドによる腫瘍治療 | |
JP2005503418A (ja) | 治療的ワクチン接種法、hiv逆転写酵素の突然変異ペプチドならびにワクチン接種及び診断目的のためのそれらの使用 | |
WO1998014587A1 (en) | Inhibition of hiv replication using soluble tat peptide analogs | |
RU2126266C1 (ru) | Способ ингибирования ретровирусной инфекции (варианты), ингибитор протеазы, кодирующая его нуклеиновая кислота и способ рекомбинантного продуцирования серинового ингибитора | |
JP2014512353A (ja) | 抗ウイルス組成物 | |
JP2018508588A (ja) | ガレクチンタンパク質を用いるレトロウイルスの潜伏感染状態の逆転法 | |
WO2004106491A2 (en) | Angiogenin-based hiv-1 therapies | |
EP1232755B1 (en) | Anti-HIV agents | |
JPH08503704A (ja) | Gp41変異体とhiv治療剤としてのそれらの使用 | |
Thimmaiah et al. | Immunomodulators and SARS-CoV-2: Management of the Dysregulated Immune Response | |
US20100256045A1 (en) | Use of Measles Virus Nucleoprotein for Treating Atherosclerosis | |
Evans | Grand round--University Hospital of Wales, Cardiff. Pyrexia of unknown origin. | |
WO2000045833A1 (en) | Hiv drug resistance system | |
US20160175388A1 (en) | Immunosuppressive components associated with retroviral replicating vectors | |
JPH08503488A (ja) | Hivのmaペプチドに基づくaidsの治療 | |
JP2005531589A (ja) | Hivの複製を阻害するための方法及び組成物 | |
JP2002529377A (ja) | Hiv+患者において薬剤耐性の発展を阻害するためのgm−csfの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004517323 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2472438 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003246119 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038024578 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003738567 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10500774 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003738567 Country of ref document: EP |